Overview

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2* in beta-thalassemia patients with deferasirox treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Deferasirox